No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Design Therapeutics To Present Update On Progress Of DT-168 Program For FECD At Eyecelerator At Park City 2025 On May 2, 2025
Press Release: Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
Bright Peak Therapeutics Appoints John Schmid to Its Board of Directors
Top Premarket Gainers
12 Health Care Stocks Moving In Friday's Pre-Market Session
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why